BoneOscopy technology has broad applications in oncology, particularly in the treatment of metastatic bone cancers. It offers an innovative approach to daily cancer monitoring, potentially leading to reduced treatment duration, better patient outcomes, and the ability to tailor treatments dynamically to individual patient responses.

• In the coming years, €4 billion will be allocated to initiatives addressing cancer prevention, early detection, treatment and recovery, notably through Flagship initiatives enhancing evidence-based decision-making, follow-up care and further research activities. The significant growth of particle radiation therapy (PRT) centres worldwide will increase the number of patients receiving particles per year, where the deployment of BoneOscopy will decrease the treatment toxicity and improve treatment outcomes.
• Approximately 15% of all new cancer patients per year (circa € 2.1 million patients yearly, assuming 14 million new patients yearly worldwide) can benefit from PRT treatments and therefore from PRT monitoring systems such as BoneOscopy.
• In addition, current statistics on cancer relapse post-therapy indicate that 20% to 60% of all patients will relapse (depending on the cancer). All metastatic patients could benefit from BoneOscopy in the management of their cancer, leading to improved treatment outcomes, better quality of life and a lower burden on the health system.